Trial Profile

A pivotal phase III clinical trial of MaaT033

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MaaT 033 (Primary)
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use
Sponsors MaaT Pharma

Most Recent Events

09 Mar 2026 According to a MaaT Pharma media release, data from this study will be presented at the 2026 EBMT Annual Meeting, taking place March 22-25, 2026 in Madrid, Spain.
05 Jul 2021 New trial record
28 Jun 2021 According to a MaaT Pharma media release, the company expects to initiate this trial next year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com